186430-23-9

Basic information

• Product Name: 5-Chloro-N-[1(S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-1H-indole-2-carboxamide
• Synonyms: CP-320626
• CAS NO: 186430-23-9
• Molecular Formula: C₂₃H₂₃ClFN₃O₃
• Molecular Weight: 443.90946
• Mol File: 186430-23-9.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: 5-Chloro-N-[1(S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-1H-indole-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-N-[1(S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-1H-indole-2-carboxamide(186430-23-9)
• EPA Substance Registry System: 5-Chloro-N-[1(S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-1H-indole-2-carboxamide(186430-23-9)

Safety Data

• Hazardous Substances Data: 186430-23-9(Hazardous Substances Data)

Upstream product

• 10517-21-2 5-chloro-1H-Indole-2-carboxylic acid 
• 186431-68-5 [(S)-1-(4-Fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 41153-30-4 Boc-Phe(p-F) 
• 5382-17-2 piperidin-4-ol hydrochloride 

Relevant articles and documents

Use of glycogen phosphorylase inhibitors

The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

Use of glycogen phosphorylase inhibitors to inhibit tumor growth

This invention relates to the use of glycogen phosphorylase inhibitors of Formula I or Formula IA: 1as defined herein, and their pharmaceutically acceptable salts and prodrugs thereof, to inhibit abnormal cell growth in mammals, including humans. The invention also relates to pharmaceutical compositions containing glycogen phosphorylase inhibitors alone or in combination with other glycogen phosphorylase inhibitors or other inhibitors of abnormal cell growth, and to methods of treating cancer, hyperproliferative disorders, or abnormal cell growth in a mammal by administering to a mammal in need thereof the compounds and compositions of the invention.

Use of glycogen phosphorylase inhibitors to inhibit tumor growth

This invention relates to the use of glycogen phosphorylase inhibitors of Formula I or Formula IA: as defined herein, and their pharmaceutically acceptable salts and prodrugs thereof, to inhibit abnormal cell growth in mammals, including humans. The invention also relates to pharmaceutical compositions containing glycogen phosphorylase inhibitors alone or in combination with other glycogen phosphorylase inhibitors or other inhibitors of abnormal cell growth, and to methods of treating cancer, hyperproliferative disorders, or abnormal cell growth in a mammal by administering to a mammal in need thereof the compounds and compositions of the invention.